Ashwagandha Does Not Directly Affect Adrenal Gland Function
The evidence provided contains no guidelines or research demonstrating that ashwagandha has direct effects on adrenal gland structure or function. The available guidelines focus exclusively on adrenal insufficiency management with pharmaceutical glucocorticoids and mineralocorticoids, not herbal supplements 1, 2, 1.
What Ashwagandha Actually Does
Cortisol Modulation (Not Adrenal Gland Changes)
Ashwagandha appears to reduce serum cortisol levels through modulation of the hypothalamic-pituitary-adrenal (HPA) axis, not by directly affecting adrenal gland tissue or hormone production capacity 3, 4.
- A 2025 meta-analysis found statistically significant cortisol reduction (-1.16 µg/dL, 95% CI: -1.64 to -0.69, P < 0.001) across multiple RCTs 5
- Morning cortisol decreased significantly with 240 mg daily dosing (P < 0.001) 3
- Doses of 125-600 mg daily showed dose-dependent cortisol reduction 6, 4
Critical distinction: Lowering cortisol output is fundamentally different from changing adrenal gland structure, function, or reserve capacity. The adrenal glands themselves remain structurally and functionally intact.
Stress and Anxiety Reduction
Multiple RCTs demonstrate stress reduction via validated scales:
- Hamilton Anxiety Rating Scale (HAM-A) showed significant improvement with 240 mg daily (P = 0.040) 3
- Perceived Stress Scale (PSS) scores decreased with both 250 mg/day (P < 0.05) and 600 mg/day (P < 0.001) 6
- However, the 2025 meta-analysis found no significant impact on perceived stress scores (SMD = -0.355, P = 0.40), despite cortisol reduction 5
This disconnect between biological markers and subjective experience warrants caution in clinical interpretation.
Evidence-Based Dosing for Healthy Adults
Based on the highest quality recent evidence:
- Minimum effective dose: 125 mg daily for stress reduction 4
- Standard dose range: 240-300 mg daily in most RCTs 3, 6, 7
- Higher dose: 500-600 mg daily showed greater effects but not necessarily proportional benefit 6, 4
- Duration: 8-12 weeks for measurable effects in clinical trials 3, 6, 7, 4
Typically administered as a single daily dose or divided twice daily.
Safety Profile
An 8-week safety study in 80 healthy volunteers (300 mg twice daily) found no adverse effects on 8:
- Hematological parameters
- Hepatic function (liver enzymes)
- Thyroid function (TSH, T3, T4)
- Vital signs or BMI
- No adverse events reported
However, a 2026 critical review identified potential concerns 9:
- Gastrointestinal side effects with prolonged use
- Hepatotoxicity risk via cytochrome P450 metabolism creating reactive intermediates
- Thyrotoxicosis cases reported
- Theoretical risk of adrenal suppression with chronic use (though no direct evidence in healthy adults)
- Drug interactions via CYP450 enzyme modulation
Critical Clinical Caveats
Populations to Avoid or Use Extreme Caution
- Patients with diagnosed adrenal insufficiency (primary or secondary) - ashwagandha is NOT a substitute for hydrocortisone replacement 1, 2, 1
- Patients on glucocorticoid therapy - potential for unpredictable HPA axis effects 10
- Thyroid disorders - reports of thyrotoxicosis 9
- Liver disease - hepatotoxicity concerns 9
- Pregnancy/lactation - insufficient safety data
Drug Interactions
Ashwagandha may interact with medications metabolized by CYP450 enzymes, similar to how grapefruit juice affects hydrocortisone metabolism 2. Consider potential interactions with:
- Immunosuppressants
- Sedatives/anxiolytics
- Thyroid medications
- Antihypertensives
What This Means for Clinical Practice
Ashwagandha does not "support" or "heal" adrenal glands. It modulates stress response through central nervous system pathways, not by changing adrenal tissue. The adrenal glands in healthy adults taking ashwagandha maintain normal structure and function.
For patients seeking stress management:
- Ashwagandha may reduce cortisol and anxiety symptoms at 240-300 mg daily for 8-12 weeks
- Monitor for hepatotoxicity and thyroid function with prolonged use
- Do not use as substitute for medical treatment of adrenal disorders
- Discontinue if any adverse effects occur
The evidence does not support long-term safety beyond 12 weeks - most trials are 8-12 weeks duration 3, 6, 7, 4. The theoretical risk of HPA axis suppression with chronic cortisol reduction remains unstudied 9.